Mixed signals: strong revenue growth (+70.3% YoY) and raised guidance are positive, but EPS miss ($0.05 vs. $0.41), downward estimate revisions post-earnings, and poor VGM scores (F for Growth and Momentum, D for Value) suggest limited near-term upside. Zacks Rank #3 (Hold) indicates in-line returns expected.
TG Therapeutics news
$56.190.00%
Close Sep 29, 2026 · split-adjustedArticles · 30 days1English, de-duplicated
Positive00% of coverage
Neutral1100%
Negative00% of coverage
About TG Therapeutics
Zacks Investment ResearchSep 2, 11:30 AM ETNeutral
GlobeNewswire Inc.Jul 16, 9:25 PM ET▼ Negative
The company is under investigation for potential fiduciary duty breaches and self-dealing by officers and directors, which raises serious corporate governance concerns and legal liability risks for shareholders.
Also mentions TGTX
Articles that tag TGTX but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology